Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics will host an investor call and webcast on October 19, 2026, at 8:00 am ET to review topline results from Part A of its Phase 3 Study '304' of VDPHL01 in over 500 males with mild-to-moderate pattern hair loss. VDPHL01 is an extended-release oral minoxidil in a three-trial registration program enrolling more than 1,600 men and women; if approved, it would be the only FDA-approved oral non-hormonal treatment for pattern hair loss.
Key figures
- Drug Name
- VDPHL01 (extended-release minoxidil tablet)
- Phase Of Trial
- Phase 3
- Study 302 enrollment men
- 519
- Study 304 enrollment men
- 536
- Total program enrollment
- more than 1,600
- Earliest patent expiration
- 2043
- Study 306 enrollment women
- 556
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.